Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Arcus Biosciences, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 180
- −18 vs. Q4 2022
- Shares held
- 55.4M
- +1.75M (+3.3%) vs. Q4 2022
- Total value
- $1.01B
- −$98.1M (−8.8%) vs. Q4 2022
- New holders
- 24
- 70 more added
- Sold out
- 42
- 60 more reduced
2 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RCUS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 231 | $3.78B |
| Q1 2026 | 211 | $2.57B |
| Q4 2025 | 209 | $2.89B |
| Q3 2025 | 190 | $1.37B |
| Q2 2025 | 186 | $811.5M |
| Q1 2025 | 187 | $763.3M |
| Q4 2024 | 186 | $1.25B |
| Q3 2024 | 187 | $815.7M |
| Q2 2024 | 193 | $790.9M |
| Q1 2024 | 172 | $997.7M |
| Q4 2023 | 185 | $1.01B |
| Q3 2023 | 187 | $947.9M |
| Q2 2023 | 181 | $1.11B |
| Q1 2023 | 180 | $1.01B |
| Q4 2022 | 200 | $1.11B |
| Q3 2022 | 183 | $1.37B |
| Q2 2022 | 173 | $1.33B |
| Q1 2022 | 157 | $1.60B |
| Q4 2021 | 142 | $2.06B |
| Q3 2021 | 131 | $1.68B |
| Q2 2021 | 130 | $1.24B |
| Q1 2021 | 148 | $1.25B |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Arcus Biosciences, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HSBC Holdings PLC | 0 | $0 | 0.00% | −13,821−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −13,495−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −11,490−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −10,896−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −10,800−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −9,400−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −8,596−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −6,415−100.0% | Sold out |
| SG3 Management, LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −2,781−100.0% | Sold out |
| Sutton Wealth Advisors Inc. | 0 | $0 | 0.00% | −827−100.0% | Sold out |
| Fifth Third Bancorp | 0 | $0 | 0.00% | −665−100.0% | Sold out |
| Anfield Capital Management, LLC | 0 | $0 | 0.00% | −531−100.0% | Sold out |
| High Net Worth Advisory Group LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Coppell Advisory Solutions LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Coppell Advisory Solutions Corp. | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Laffer Tengler Investments | 0 | $0 | 0.00% | −180−100.0% | Sold out |
| Private Trust Co NA | 0 | $0 | 0.00% | −57−100.0% | Sold out |
| Bell Investment Advisors, Inc | 0 | $0 | 0.00% | −37−100.0% | Sold out |
| Global Retirement Partners, LLC | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| Versant Capital Management, Inc | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| SJS Investment Consulting Inc. | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Monarch Partners Asset Management LLC | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |